Details: pack, label wording, sources, registration
Otobrol 8 mg, Coated tablet
film-coated tablet, human medicine
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog
Off-label oral ondansetron for short-term control of clinically important nausea and active vomiting in dogs
5.8/10
Weak evidence support
Details →
vetman assessment
Otobrol
×
8 mg, film-coated tablet, human medicine
Assessed clinical scope Dog · Off-label oral ondansetron for short-term control of clinically important nausea and active vomiting in dogs · By mouth
Care setting Veterinary-prescribed home or step-down treatment only when the calculated dose can be delivered accurately and the cause of nausea or vomiting is being investigated and treated
vetman score
5.8/10
Weak evidence support
Evidence confidence: Medium
Georgia: Yes, human · № რ-042444 · Verified on 16 Oct 2026
Off-label use
Ondansetron can help canine nausea, but this whole-only 8 mg human tablet combines coarse dose delivery with newly documented poor and variable oral exposure. Use only when the calculated dose is genuinely deliverable and response can be reviewed; otherwise choose a more accurate formulation or route.
Regulatory and scientific credibility 6.5/10
The exact human presentation has sourced current registrations in Georgia and EU/EEA, with an identifiable manufacturer and strength. It has no veterinary authorisation, no checked UK or US exact trade-name registration, and its animal use remains off-label.
Clinical efficacy 5.5/10
Ondansetron has credible canine anti-nausea activity, but two direct oral studies found poor and highly variable exposure: mean bioavailability was about 5% in healthy dogs and 25% of hospitalised dogs had no detectable drug. Clinical improvement without a controlled comparator does not resolve that efficacy uncertainty.
Safety and tolerability 6.5/10
Ondansetron is generally well tolerated at veterinary doses, but these exact human products have no dog- or cat-specific safety dossier. QT prolongation, serotonergic toxicity, constipation or masking of ileus, hypersensitivity and altered clearance in severe hepatic disease require patient and drug-list review; reproductive and paediatric veterinary safety is not established.
Clinical practicality 4.0/10
The catalogue records this as a whole-only 8 mg tablet. It can directly match only selected dog weights and dose targets; most small dogs and dose adjustments require a lower-strength or validated compounded preparation. Repeated administration and poor oral exposure further reduce practicality.
Full-course cost-effectiveness -
Price was not assessed and is excluded from the overall score.
Important safety and use flags
Do not combine with apomorphine: profound hypotension and loss of consciousness have been reported. This is especially relevant when apomorphine is being considered as an emetic in a dog. Rule out gastrointestinal obstruction, progressive ileus and gastric distension when clinically plausible. Ondansetron is not prokinetic and suppression of vomiting must not delay diagnosis or decompression. Review congenital long-QT risk, bradyarrhythmia, heart failure, hypokalaemia or hypomagnesaemia and other QT-prolonging drugs; use ECG monitoring when the combined risk is clinically important. Review serotonergic medicines and monitor for agitation, tremor, hyperreflexia, hyperthermia, diarrhoea or autonomic instability; stop and reassess if serotonin toxicity is suspected. Severe hepatic disease may reduce clearance and increase exposure. Use the lowest effective regimen and reassess interval, adverse effects and concurrent hepatically cleared medicines. Do not use after hypersensitivity to ondansetron or another 5-HT3 antagonist; rare anaphylaxis and bronchospasm require immediate treatment. Correct dehydration and clinically important electrolyte or acid-base disturbance, investigate the underlying cause and track vomiting, nausea behaviour, intake and bowel function. Symptom control is not treatment of the disease. This catalogue presentation is an 8 mg whole-only tablet. Do not estimate a feline or small-dog dose from an unmeasured fraction of crushed powder; use an accurately measurable lower strength or validated pharmacy compound. Assessment sources +
Close
Cat
Off-label oral ondansetron for short-term control of clinically important nausea and active vomiting in cats
5.3/10
Weak evidence support
Details →
vetman assessment
Otobrol
×
8 mg, film-coated tablet, human medicine
Assessed clinical scope Cat · Off-label oral ondansetron for short-term control of clinically important nausea and active vomiting in cats · By mouth
Care setting Veterinary-prescribed home or step-down treatment only when the calculated dose can be delivered accurately and the cause of nausea or vomiting is being investigated and treated
vetman score
5.3/10
Weak evidence support
Evidence confidence: Medium
Georgia: Yes, human · № რ-042444 · Verified on 16 Oct 2026
Off-label use
Ondansetron has a recognised feline role, but a whole-only 8 mg human tablet is a poor match for the small feline dose and oral evidence remains limited. Prefer an accurately measurable lower-strength or validated compounded preparation and reassess the cause and response rather than escalating blindly.
Regulatory and scientific credibility 6.5/10
The exact human presentation has sourced current registrations in Georgia and EU/EEA, with an identifiable manufacturer and strength. It has no veterinary authorisation, no checked UK or US exact trade-name registration, and its animal use remains off-label.
Clinical efficacy 5.5/10
Feline consensus includes oral ondansetron and cat pharmacokinetics found about 32% oral bioavailability, but direct controlled clinical evidence is limited and concentrated in induced or peri-anaesthetic emesis. Evidence cannot establish reliable benefit for every naturally occurring vomiting syndrome.
Safety and tolerability 6.5/10
Ondansetron is generally well tolerated at veterinary doses, but these exact human products have no dog- or cat-specific safety dossier. QT prolongation, serotonergic toxicity, constipation or masking of ileus, hypersensitivity and altered clearance in severe hepatic disease require patient and drug-list review; reproductive and paediatric veterinary safety is not established.
Clinical practicality 1.0/10
A whole-only 8 mg tablet is far above the usual calculated feline dose. Crushing does not make informal powder division accurate or validated; most cats require a lower-strength liquid or pharmacy-prepared patient-specific dose, while the oral route itself has only moderate bioavailability.
Full-course cost-effectiveness -
Price was not assessed and is excluded from the overall score.
Important safety and use flags
Do not combine with apomorphine: profound hypotension and loss of consciousness have been reported. This is especially relevant when apomorphine is being considered as an emetic in a dog. Rule out gastrointestinal obstruction, progressive ileus and gastric distension when clinically plausible. Ondansetron is not prokinetic and suppression of vomiting must not delay diagnosis or decompression. Review congenital long-QT risk, bradyarrhythmia, heart failure, hypokalaemia or hypomagnesaemia and other QT-prolonging drugs; use ECG monitoring when the combined risk is clinically important. Review serotonergic medicines and monitor for agitation, tremor, hyperreflexia, hyperthermia, diarrhoea or autonomic instability; stop and reassess if serotonin toxicity is suspected. Severe hepatic disease may reduce clearance and increase exposure. Use the lowest effective regimen and reassess interval, adverse effects and concurrent hepatically cleared medicines. Do not use after hypersensitivity to ondansetron or another 5-HT3 antagonist; rare anaphylaxis and bronchospasm require immediate treatment. Correct dehydration and clinically important electrolyte or acid-base disturbance, investigate the underlying cause and track vomiting, nausea behaviour, intake and bowel function. Symptom control is not treatment of the disease. This catalogue presentation is an 8 mg whole-only tablet. Do not estimate a feline or small-dog dose from an unmeasured fraction of crushed powder; use an accurately measurable lower strength or validated pharmacy compound. Assessment sources +
Close
Administration route
By mouth
Registration
Georgia
Yes, human
In force until 28 Nov 2029
Human (Ministry of Health, RAMA)
In the register: ოტობროლი 8 მგ, აბი
№ რ-042444
Verified on: 16 Oct 2026
EU
Yes, human
UK
No
US
No
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026
